Aethlon Medical Inc (AEMD) - Net Assets
Based on the latest financial reports, Aethlon Medical Inc (AEMD) has net assets worth $6.71 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.06 Billion) and total liabilities ($1.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aethlon Medical Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.71 Billion |
| % of Total Assets | 83.32% |
| Annual Growth Rate | 31.55% |
| 5-Year Change | -44.87% |
| 10-Year Change | 241.03% |
| Growth Volatility | 282.84 |
Aethlon Medical Inc - Net Assets Trend (1997–2025)
This chart illustrates how Aethlon Medical Inc's net assets have evolved over time, based on quarterly financial data. Also explore Aethlon Medical Inc (AEMD) total assets for the complete picture of this company's asset base.
Annual Net Assets for Aethlon Medical Inc (1997–2025)
The table below shows the annual net assets of Aethlon Medical Inc from 1997 to 2025. For live valuation and market cap data, see Aethlon Medical Inc (AEMD) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $5.12 Million | -11.15% |
| 2024-03-31 | $5.77 Million | -61.72% |
| 2023-03-31 | $15.06 Million | -11.34% |
| 2022-03-31 | $16.99 Million | +82.83% |
| 2021-03-31 | $9.29 Million | +0.18% |
| 2020-03-31 | $9.28 Million | +303.53% |
| 2019-03-31 | $2.30 Million | -61.89% |
| 2018-03-31 | $6.03 Million | +913.21% |
| 2017-03-31 | $595.41K | -60.37% |
| 2016-03-31 | $1.50 Million | +130.64% |
| 2015-03-31 | $651.38K | +104.42% |
| 2014-03-31 | $-14.73 Million | -61.08% |
| 2013-03-31 | $-9.14 Million | +1.63% |
| 2012-03-31 | $-9.30 Million | -55.56% |
| 2011-03-31 | $-5.98 Million | -35.74% |
| 2010-03-31 | $-4.40 Million | -11.47% |
| 2009-03-31 | $-3.95 Million | -18.87% |
| 2008-03-31 | $-3.32 Million | +53.15% |
| 2007-03-31 | $-7.09 Million | -303.05% |
| 2006-03-31 | $-1.76 Million | +42.63% |
| 2005-03-31 | $-3.07 Million | +16.09% |
| 2004-03-31 | $-3.66 Million | -0.82% |
| 2003-03-31 | $-3.63 Million | -64.98% |
| 2002-03-31 | $-2.20 Million | +10.89% |
| 2001-03-31 | $-2.47 Million | -245.84% |
| 2000-03-31 | $-713.05K | -1.21% |
| 1999-03-31 | $-704.50K | -57409.88% |
| 1998-03-31 | $-1.23K | -151.60% |
| 1997-03-31 | $2.37K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aethlon Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16791966900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.59K | 0.05% |
| Other Comprehensive Income | $-17.13K | -0.33% |
| Other Components | $173.09 Million | 3378.39% |
| Total Equity | $5.12 Million | 100.00% |
Aethlon Medical Inc Competitors by Market Cap
The table below lists competitors of Aethlon Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NorCom Information Technology GmbH & Co. KGaA
XETRA:NC5A
|
$2.79 Million |
|
Cottonindo Ariesta Tbk PT
JK:KPAS
|
$2.79 Million |
|
Animalcare Group Plc
LSE:ANCR
|
$2.79 Million |
|
MODERN LAND (CHINA) DL-01
F:7PJ
|
$2.79 Million |
|
Lyc Healthcare Bhd
KLSE:0075
|
$2.79 Million |
|
Planet Properindo Jaya Pt
JK:PLAN
|
$2.78 Million |
|
Mercator Limited
NSE:MERCATOR
|
$2.78 Million |
|
Cooper Metals Ltd
AU:CPM
|
$2.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aethlon Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,766,332 to 5,123,530, a change of -642,802 (-11.1%).
- Net loss of 13,388,089 reduced equity.
- New share issuances of 3,539,907 increased equity.
- Other comprehensive income decreased equity by 10,193.
- Other factors increased equity by 9,215,573.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.39 Million | -261.31% |
| Share Issuances | $3.54 Million | +69.09% |
| Other Comprehensive Income | $-10.19K | -0.2% |
| Other Changes | $9.22 Million | +179.87% |
| Total Change | $- | -11.15% |
Book Value vs Market Value Analysis
This analysis compares Aethlon Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-03-31 | $13.98 | $2.30 | x |
| 1998-03-31 | $-7.21 | $2.30 | x |
| 1999-03-31 | $-3506.70 | $2.30 | x |
| 2000-03-31 | $-2047.24 | $2.30 | x |
| 2001-03-31 | $-6652.26 | $2.30 | x |
| 2002-03-31 | $-4292.90 | $2.30 | x |
| 2003-03-31 | $-4896.81 | $2.30 | x |
| 2004-03-31 | $-3350.91 | $2.30 | x |
| 2005-03-31 | $-1638.69 | $2.30 | x |
| 2006-03-31 | $-674.96 | $2.30 | x |
| 2007-03-31 | $-1974.46 | $2.30 | x |
| 2008-03-31 | $-724.44 | $2.30 | x |
| 2009-03-31 | $-689.67 | $2.30 | x |
| 2010-03-31 | $-583.15 | $2.30 | x |
| 2011-03-31 | $-643.84 | $2.30 | x |
| 2012-03-31 | $-913.44 | $2.30 | x |
| 2013-03-31 | $-4596.12 | $2.30 | x |
| 2014-03-31 | $-5777.17 | $2.30 | x |
| 2015-03-31 | $16.50 | $2.30 | x |
| 2016-03-31 | $31.50 | $2.30 | x |
| 2017-03-31 | $13.07 | $2.30 | x |
| 2018-03-31 | $74.70 | $2.30 | x |
| 2019-03-31 | $200.70 | $2.30 | x |
| 2020-03-31 | $275.55 | $2.30 | x |
| 2021-03-31 | $78.00 | $2.30 | x |
| 2022-03-31 | $116.08 | $2.30 | x |
| 2023-03-31 | $73.34 | $2.30 | x |
| 2024-03-31 | $22.95 | $2.30 | x |
| 2025-03-31 | $32.83 | $2.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aethlon Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -261.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.44x
- Recent ROE (-261.31%) is below the historical average (-126.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -64.62% | 0.00% | 0.00x | 1.15x | $-1.77K |
| 1998 | 0.00% | -17.96% | 26.57x | 0.00x | $-3.48K |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-282.23K |
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.23 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.18 Million |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.78 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.10 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.15 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.79 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.74 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.32 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.81 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.69 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.13 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.11 Million |
| 2012 | 0.00% | -596.40% | 1.62x | 0.00x | $-7.18 Million |
| 2013 | 0.00% | -397.72% | 2.48x | 0.00x | $-3.98 Million |
| 2014 | 0.00% | -822.48% | 0.96x | 0.00x | $-11.86 Million |
| 2015 | -1104.40% | -891.51% | 0.55x | 2.24x | $-6.86 Million |
| 2016 | -313.77% | -549.53% | 0.35x | 1.65x | $-5.03 Million |
| 2017 | -1075.73% | -1855.78% | 0.23x | 2.55x | $-7.34 Million |
| 2018 | -92.60% | -3796.16% | 0.02x | 1.20x | $-6.29 Million |
| 2019 | -255.45% | -2697.88% | 0.06x | 1.70x | $-6.44 Million |
| 2020 | -67.74% | -980.33% | 0.06x | 1.10x | $-7.31 Million |
| 2021 | -83.22% | -1190.76% | 0.06x | 1.13x | $-8.79 Million |
| 2022 | -60.80% | -3540.90% | 0.02x | 1.13x | $-12.13 Million |
| 2023 | -79.86% | -2094.89% | 0.03x | 1.16x | $-13.54 Million |
| 2024 | -211.71% | 0.00% | 0.00x | 1.43x | $-12.78 Million |
| 2025 | -261.31% | 0.00% | 0.00x | 1.44x | $-13.90 Million |
Industry Comparison
This section compares Aethlon Medical Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,702,078,358
- Average return on equity (ROE) among peers: -73.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aethlon Medical Inc (AEMD) | $6.71 Billion | -64.62% | 0.20x | $2.79 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Aethlon Medical Inc
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Di… Read more